The aim of our study was to examine TFF1 level distribution in breast carcinomas in order to distinguish estrogen-independent from estrogen-dependent TFF1 expression and to evaluate clinical usefulness of TFF1 status in early breast cancer during the first 3 years of follow-up. TFF1 is regarded as a predictive factor for positive response to endocrine therapy in breast cancer patients. A role of an estrogen-regulated, autocrine motogenic factor was assumed to be a major biological role of trefoil factor 1 (TFF1) in breast cancer. File import instruction Abstractīackground. Select the file that you have just downloaded and select import option Reference Manager (RIS). Trefoil Factor 1 in Early Breast Carcinoma: A Potential Indicator of Clinical Outcome during the First 3 Years of Follow-Up. Markićević M, Džodić R, Buta M, Kanjer K, Mandušić V, Nešković-Konstantinović Z, Nikolić-Vukosavljević D. ✉ Corresponding author: Milan Markićević, Department of Experimental Oncology, Institute for Oncology and Radiology of Serbia, Pasterova 14, 11000 Belgrade, Serbia, markicevicac.rs. Clinic of Medical Oncology, Institute for Oncology and Radiology of Serbia, Pasterova 14, 11000 Belgrade, Serbia. Vinča Institute of Nuclear Science, Mike Petrovića Alasa 12-14, 11000 Belgrade, Serbia ĥ. University of Belgrade School of Medicine, Dr Subotića 8, 11000 Belgrade, Serbia Ĥ. Surgical Oncology Clinic, Institute for Oncology and Radiology of Serbia, Pasterova 14, 11000 Belgrade, Serbia ģ. Department of Experimental Oncology, Institute for Oncology and Radiology of Serbia, Pasterova 14, 11000 Belgrade, Serbia Ģ. Milan Markićević 1, Radan Džodić 2,3, Marko Buta 2, Ksenija Kanjer 1, Vesna Mandušić 4, Zora Nešković-Konstantinović 5, Dragica Nikolić-Vukosavljević 1ġ.

Research Paper Trefoil Factor 1 in Early Breast Carcinoma: A Potential Indicator of Clinical Outcome during the First 3 Years of Follow-Up

Trefoil by M.C. Moore